Metastases to rectum – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 12:24:25 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Metastases to rectum – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effectiveness of Floxuridine in Patients with Resectable Colorectal Liver Metastases and Low Clinical Risk Score https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-floxuridine-in-patients-with-resectable-colorectal-liver-metastases-and-low-clinical-risk-score/ Wed, 29 Apr 2026 14:58:31 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-floxuridine-in-patients-with-resectable-colorectal-liver-metastases-and-low-clinical-risk-score/ This clinical trial is focused on studying the treatment of colorectal cancer that has spread to the liver, known as colorectal liver metastases. The treatment being tested is called hepatic arterial infusion pump (HAIP) chemotherapy, which involves delivering chemotherapy directly to the liver through a pump. The specific drug used in this treatment is floxuridine, a type of medication that helps to stop cancer cells from growing. The trial aims to compare the effectiveness of surgery combined with HAIP chemotherapy to surgery alone in patients with a low clinical risk score, which means they have a lower chance of the cancer spreading further.

Participants in the study will undergo surgery to remove the liver metastases, and some will receive additional HAIP chemotherapy. The study will monitor how long patients live without the cancer getting worse, known as progression-free survival. Other aspects being observed include overall survival, the occurrence of any side effects, and the quality of life of the participants. The trial will also look at how well the chemotherapy is absorbed and processed by the body, as well as the cost-effectiveness of the treatment.

The study is expected to continue until June 2026, with the goal of providing valuable information on whether adding HAIP chemotherapy to surgery can improve outcomes for patients with colorectal liver metastases. This research could potentially lead to better treatment options for individuals facing this type of cancer.

]]>